Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Methanesulfonanilides for the treatment of inflammatory disorders

The University of Edinburgh
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models.

Mechanism of action

ERG specific methanesulfonanilides, a family of Class III anti-arrhythmics, have been shown to modulate leukocyte and macrophage function

Full description

Class III anti- arrhythmics can modulate the recruitment of inflammatory leukocytes and phagocytosis of apoptotic infiltrated cells. The discovery has application in treatment of chronic, acute and fibrogenic mediated inflammation. Researchers have identified a novel mechanism for regulation of phagocytosis via inhibition of the mammalian receptor encoded by the ether-a-go-go related gene (ERG). The ERG specific methanesulfonanilides, a family of Class III anti-arrhythmics, have been shown to modulate leukocyte and macrophage function, reducing recruitment to sites of inflammation, promoting phagocytosis of apoptotic cells, and inhibiting phlogistic responses. The effectiveness of the drugs in the resolution of the inflammatory response was proved in several animal models of established Leukocyte mediated inflammation. The therapeutic application of ERG-specific methanesulfoanalides presents a powerful new approach for the treatment of inflammatory disorders.

Development status

Early Stage

Patent information

A PCT application was filed for this technology in October 2006.

Type of business relationship sought

The University of Edinburgh is now looking to take the research on towards product development and is seeking industrial partners to license or fund development of this technology.
Partnering consultation free of charge
Maximizing Pharmaceutical Patent Lifecycles
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us